Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Dow
Merck
McKesson
Baxter

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for Rimiducid


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Rimiducid?

Rimiducid is an investigational drug.

There have been 20 clinical trials for Rimiducid. The most recent clinical trial was a Phase 1 trial, which was initiated on December 27th 2018.

The most common disease conditions in clinical trials are Myelodysplastic Syndromes, Preleukemia, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are Bellicum Pharmaceuticals, Poseida Therapeutics, Inc., and National Cancer Institute (NCI).

There are nineteen US patents protecting this investigational drug and fifty-eight international patents.

Recent Clinical Trials for Rimiducid
TitleSponsorPhase
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple MyelomaPoseida Therapeutics, Inc.Phase 1
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST TrialNational Cancer Institute (NCI)Phase 1
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)Poseida Therapeutics, Inc.Phase 1

See all Rimiducid clinical trials

Clinical Trial Summary for Rimiducid

Top disease conditions for Rimiducid
Top clinical trial sponsors for Rimiducid

See all Rimiducid clinical trials

US Patents for Rimiducid

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Rimiducid ⤷  Try it Free Bispecific chimeric antigen receptors and methods of use thereof to treat cancer Seattle Children's Hospital (Seattle, WA) ⤷  Try it Free
Rimiducid ⤷  Try it Free Chimeric NK receptor and methods for treating cancer TRUSTEES OF DARTMOUTH COLLEGE (Hanover, NH) ⤷  Try it Free
Rimiducid ⤷  Try it Free NKP30 receptor targeted therapeutics THE TRUSTEES OF DARTMOUTH COLLEGE (Hanover, NH) ⤷  Try it Free
Rimiducid ⤷  Try it Free T-cell receptor-deficient t cell compositions THE TRUSTEES OF DARTMOUTH COLLEGE (Hanover, NH) ⤷  Try it Free
Rimiducid ⤷  Try it Free T-cell receptor-deficient T cell compositions THE TRUSTEES OF DARTMOUTH COLLEGE (Hanover, NH) ⤷  Try it Free
Rimiducid ⤷  Try it Free T cell receptor-deficient T cell compositions THE TRUSTEES OF DARTMOUTH COLLEGE (Hanover, NH) ⤷  Try it Free
Rimiducid ⤷  Try it Free T cell receptor-deficient T cell compositions THE TRUSTEES OF DARTMOUTH COLLEGE (Hanover, NH) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Rimiducid

Drugname Country Document Number Estimated Expiration Related US Patent
Rimiducid Australia AU2013221672 2032-02-13 ⤷  Try it Free
Rimiducid Australia AU2017264982 2032-02-13 ⤷  Try it Free
Rimiducid Australia AU2020203137 2032-02-13 ⤷  Try it Free
Rimiducid Canada CA2861491 2032-02-13 ⤷  Try it Free
Rimiducid European Patent Office EP2814846 2032-02-13 ⤷  Try it Free
Rimiducid European Patent Office EP3594245 2032-02-13 ⤷  Try it Free
Rimiducid Spain ES2774160 2032-02-13 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Dow
Merck
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.